Vir Biotechnology Appoints Jason O’Byrne as Chief Financial Officer
2024年9月10日 - 9:05PM
ビジネスワイヤ（英語）
– Seasoned biotech executive brings decades of
effective financial leadership to Vir –
Vir Biotechnology Inc. (Nasdaq: VIR) today announced that Jason
O’Byrne, MBA, is appointed as Executive Vice President and Chief
Financial Officer (CFO), effective October 2, 2024. Mr. O’Byrne
will join the Vir Executive Management Team and report directly to
the company’s Chief Executive Officer, Marianne De Backer, M.Sc.,
Ph.D., MBA.
Mr. O’Byrne is an accomplished executive with more than 20 years
of experience in finance and operations. He is a recognized
champion of financial discipline and brings demonstrated financial
leadership in capital allocation and formation, corporate strategy,
and operational execution.
Mr. O’Byrne joins Vir from Caribou Biosciences, Inc., where he
served as CFO leading the finance, investor relations, corporate
communications, IT, procurement and operations functions as the
company advanced its pipeline of clinical-stage cell therapies in
oncology and autoimmune disease. Prior to joining Caribou, Mr.
O’Byrne served as Senior Vice President of Finance at Audentes
Therapeutics, where he led financial operations of the gene therapy
company. While at Audentes, Mr. O’Byrne oversaw the financial due
diligence and integration related to the company’s acquisition by
Astellas Pharma in 2020.
Earlier in his career, Mr. O’Byrne held roles of increasing
responsibility and geographical reach at Genentech, a member of the
Roche group. Over a 13-year period with Genentech, he built broad
operational finance expertise across manufacturing, research,
clinical development, business development and commercialization.
During his tenure, he served as Regional Head of Commercial Finance
for the Asia Pacific Region, and Global Head of Finance for Product
Development. Mr. O’Byrne holds a Bachelor of Applied Science in
Mechanical Engineering from the University of British Columbia, and
an MBA in Finance from the New York University Stern School of
Business.
“I am delighted to welcome Jason to the Vir Executive Management
Team and excited about the impact he will bring to Vir. Jason’s
exceptional leadership coupled with his proven track record in
financial strategy across public companies, make him the perfect
fit as we embark on the next chapter for our organization,” said
Marianne De Backer, Chief Executive Officer, Vir Biotechnology. “As
a seasoned and well-respected cross-functional leader with a focus
on excellence in execution, I look forward to partnering with Jason
as we advance in our mission of powering the immune system to
transform lives.”
“I am honored to join Vir at this important time as it expands
into oncology and continues the innovative work to address unmet
patient need in infectious disease,” said Mr. O’Byrne. “I admire
Vir’s proven ability to accelerate differentiated antibody
therapeutics. I am excited to join the talented team and contribute
to rapidly advancing important new therapeutic options for
patients.”
About Vir Biotechnology, Inc.
Vir Biotechnology, Inc. is a clinical-stage biopharmaceutical
company focused on powering the immune system to transform lives by
discovering and developing medicines for serious infectious
diseases and cancer. Vir’s clinical-stage portfolio includes
infectious disease programs for chronic hepatitis delta and chronic
hepatitis B infections, in addition to multiple oncology programs.
Vir also has a preclinical portfolio of programs across a range of
other infectious diseases and oncologic malignancies. Vir routinely
posts information that may be important to investors on its
website.
Forward-Looking Statements
This press release contains forward-looking statements within
the meaning of the Private Securities Litigation Reform Act of
1995. Words such as “may,” “will,” “plan,” “potential,” “aim,”
“expect,” “anticipate,” “promising” and similar expressions (as
well as other words or expressions referencing future events,
conditions or circumstances) are intended to identify
forward-looking statements. These forward-looking statements are
based on Vir’s expectations and assumptions as of the date of this
press release. Forward-looking statements contained in this press
release include, but are not limited to, statements regarding Vir’s
strategy and plans, and its expectations related thereto, and
potential of, and expectations for, Vir’s pipeline. Many factors
may cause differences between current expectations and actual
results, including unexpected safety or efficacy data or results
observed during clinical trials or in data readouts; the occurrence
of adverse safety events; risks of unexpected costs, delays or
other unexpected hurdles; difficulties in collaborating with other
companies; successful development and/or commercialization of
alternative product candidates by Vir’s competitors; changes in
expected or existing competition; delays in or disruptions to Vir’s
business or clinical trials due to geopolitical changes or other
external factors; and unexpected litigation or other disputes. Drug
development and commercialization involve a high degree of risk,
and only a small number of research and development programs result
in commercialization of a product. Results in early-stage clinical
trials may not be indicative of full results or results from later
stage or larger scale clinical trials and do not ensure regulatory
approval. You should not place undue reliance on these statements,
or the scientific data presented. Other factors that may cause
actual results to differ from those expressed or implied in the
forward-looking statements in this press release are discussed in
Vir’s filings with the U.S. Securities and Exchange Commission,
including the section titled “Risk Factors” contained therein.
Except as required by law, Vir assumes no obligation to update any
forward-looking statements contained herein to reflect any change
in expectations, even as new information becomes available.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20240910506268/en/
Media Arran Attridge Senior Vice President, Corporate
Communications aattridge@vir.bio
Investors Richard Lepke Senior Director, Investor
Relations rlepke@vir.bio
Vir Biotechnology (NASDAQ:VIR)
過去 株価チャート
から 11 2024 まで 12 2024
Vir Biotechnology (NASDAQ:VIR)
過去 株価チャート
から 12 2023 まで 12 2024
